Your browser doesn't support javascript.
Does Methylene Blue Satisfy an Option in COVID-19 ARDS.
Yella, Sri Hari Tanguturi; Yella, Sree Sudha Tanguturi; Sasanka, Kota Sesha Brahma Shree Krishna; Thangaraju, Pugazhenthan.
  • Yella SHT; Critical Care Medicine, Omni Hospital, Hyderabad, India.
  • Yella SST; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Deoghar, Jharkhand, India.
  • Sasanka KSBSK; Department of ENT & HNS, All India Institute of Medical Sciences (AIIMS), Deoghar, Jharkhand, India.
  • Thangaraju P; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India.
Infect Disord Drug Targets ; 22(6): 62-65, 2022.
Article in English | MEDLINE | ID: covidwho-2022295
ABSTRACT

BACKGROUND:

In COVID-19, the respiratory tract is usually affected by SARS-CoV-2 infection. Due to viral transmission in the blood and an overwhelming inflammatory response, including cytokine storm, the condition can progress to acute respiratory distress syndrome and failure. Methylene blue is the only medicine that has been shown to reduce the excessive generation of reactive species and cytokines. CASE PRESENTATION A 51-year-old male patient came to the hospital with shortness of breath. At room air, the patient was having 70% Spo2. The patient was treated with a noninvasive ventilator (NIV) and Standard of care (SOC). Due to prolonged hypoxia and respiratory distress, the patient was treated with NIV and the methylene blue (MB) was given in a humidifier for 5 days.

RESULT:

Methylene blue resulted in a significant decrease in respiratory distress and a steep rise in Spo2.

CONCLUSION:

We suggest trying methylene blue as an additional intervention in COVID-related acute respiratory distress to avoid the disease's devastating consequences.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / COVID-19 Type of study: Case report Limits: Humans / Male / Middle aged Language: English Journal: Infect Disord Drug Targets Journal subject: Communicable Diseases / Drug Therapy Year: 2022 Document Type: Article Affiliation country: 1871526522666220317155947

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Respiratory Distress Syndrome / COVID-19 Type of study: Case report Limits: Humans / Male / Middle aged Language: English Journal: Infect Disord Drug Targets Journal subject: Communicable Diseases / Drug Therapy Year: 2022 Document Type: Article Affiliation country: 1871526522666220317155947